Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD
Study
Inclusion/Exclusion Baseline
Description Intervention
Criteria/Population Measures Outcomes
Author:
Intervention:
Inclusion criteria: Problem behavior: Overall ratings:
King et al., Week 1 (run-in): • Diagnosis of autism by ABC-irritability, CGI-rate illness
2001
2.5mg/kg/day placebo DSM-IV and ICD-10 mean (range): severity, (success
Country: given to both groups criteria using ADI-R and G1: 19.1 (3-38) rate %):
US
Week 2: amantadine ADOS-G
G2: 18.7 (3-33) G1: 53
Practice
setting:
Academic
Intervention
setting: Clinic
Enrollment
period:
NR
Funding:
Cerebrus PLC
Author industry
relationship
disclosures:
NR
Design:
Multi-center,
Double-blind,
randomized,
chloride or placebo given • ABC-CV subscales for
2.5mg/day at breakfast irritability (subscale I) Commonly
Week 3-5: amantadine and hyperactivity occurring
chloride or placebo given (subscale IV) were > age comorbidities:
2.5mg/kg 2 times per day adjusted 75 percentile ABC-hyperactivity,
at breakfast and afternoon • VABS age equivalent > mean (range):
18 mos
G1: 29.4 (16-42)
Assessments:
Exclusion criteria: G2: 32.7 (17-46)
Visit 0: screen (subject • IQ score 1month remained on
White:
medication
G1: 15(79)
G1: 4 (20)
G2: 15 (75)
G2: 6 (30)
Other:
G1: 4 (21)
Frequency of contact
G2: 5 (25)
during study:
morbidities:
ABC-hyperactivity
(parent-rated),
mean change
(95% CI):
Parent :
G1: -4.9
G2: -1.6
Every week
SES:
Maternal education: NR
Total: -4.81 (-
11.63 to 2.00)
Care provider:
Household income: NR
-5.75 (-11.39 to -
0.1)
King et al.,
2001 (continued)
Concomitant therapies:
SSRI:
G1: 4/19
G2: 6/20
N at enrollment:
G1: 19
G2: 20
N at follow-up:
G1: 19
Diagnostic approach:
In Study
Diagnostic tool/method:
DSM-IV, ICD-9, ABC-CV,
C-399
Harms, n (%):
Insomnia: